Maher, Toby M.
Simpson, Juliet K.
Porter, Joanna C.
Wilson, Frederick J.
Chan, Robert
Eames, Rhena
Cui, Yi
Siederer, Sarah
Parry, Simon
Kenny, Julia
Slack, Robert J.
Sahota, Jagdeep
Paul, Lyn
Saunders, Peter
Molyneaux, Philip L.
Lukey, Pauline T.
Rizzo, Gaia
Searle, Graham E.
Marshall, Richard P.
Saleem, Azeem
Kang’ombe, Arthur R.
Fairman, David
Fahy, William A.
Vahdati-Bolouri, Mitra
Funding for this research was provided by:
GlaxoSmithKline (N/a)
Article History
Received: 23 December 2019
Accepted: 18 March 2020
First Online: 26 March 2020
Ethics approval and consent to participate
: The study was approved by the London - Central Research Ethics Committee, UK (reference 17/LO/0284; IRAS: 221453), Medicine and Healthcare Products Regulatory Agency (MHRA; EudraCT number: 2016–003674-41) and permission to administer radioisotopes was obtained from the Administration of Radioactive Substances Advisory Committee of the UK (Ref: 630/3925/36090). Written informed consent was obtained from all participants prior to participation.
: Not applicable.
: TMM has received consultancy fees and, via his institution, has received research funding from GlaxoSmithKline (GSK). JCP received funding from GSK for a clinical fellow but received no personal fees and has no other disclosures. PLM via his institution has received industry-academic funding from AstraZeneca and has received speaker and consultancy fees from Boehringer Ingelheim and Hoffman-La Roche which fall outside the submitted work. GR, GES and AS are employees of Invicro; and GES and AS are former employees of GSK. JKS, FJW, RC, RE, YC, SS, SP, JK, DF, WAH and MVB are employees of and shareholders in GSK. PTL is a former employee of and owns shares in GSK and is now an independent consultant (Target to Treatment Consulting Ltd). RJS, RPM and ARK are former employees of and current shareholders in GSK. JS, LP and PS declare they have no competing interests.